J.Safra Asset Management Corp Dyne Therapeutics, Inc. Transaction History
J.Safra Asset Management Corp
- $1.2 Billion
- Q4 2024
A detailed history of J.Safra Asset Management Corp transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 11 shares of DYN stock, worth $129. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11
Previous 11
-0.0%
Holding current value
$129
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
212Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$94.6 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$87.2 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$87.1 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$79.1 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$75.3 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $611M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...